Shares of iBio, Inc. (NYSEMKT:IBIO – Get Free Report) traded down 9% on Wednesday . The stock traded as low as $2.32 and last traded at $2.32. 188,341 shares traded hands during mid-day trading, an increase of 66% from the average session volume of 113,212 shares. The stock had previously closed at $2.55.
iBio Price Performance
The firm’s fifty day simple moving average is $2.39 and its 200-day simple moving average is $2.19. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04.
iBio Company Profile
iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
Featured Articles
- Five stocks we like better than iBio
- 3 Best Fintech Stocks for a Portfolio Boost
- How Whitestone REIT is Transforming Sunbelt Retail Growth
- Consumer Staples Stocks, Explained
- Top-Performing Non-Leveraged ETFs This Year
- Profitably Trade Stocks at 52-Week Highs
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
